Aduhelm

Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate. What Happened:  Biogen and Eisai said the global Phase 3 confirmatory study, "Clarity...

The commercial failure of Biogen Inc's (NASDAQ: BIIB) drug Aduhelm has put a new focus on the research into the causes of Alzheimer's disease. Aduhelm was expected as a potential blockbuster that targeted a root cause of the disease by clearing a protein known as amyloid from the...

Centers for Medicare and Medicaid Services (CMS) finalized its decision to restrict coverage for Biogen Inc's (NASDAQ: BIIB) Alzheimer's drug Aduhelm and other amyloid-targeted drugs to just patients participating in clinical trials. "Monoclonal antibodies...

It's been about four months since Biogen, Inc. (NASDAQ: BIIB) received approval for its controversial Alzheimer's treatment Aduhelm. The initial broad approval was later narrowed by the FDA. The "Aduhelm opportunity" for the biopharma is underappreciated, an analyst said Thursday...

Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) launched a real-world, Phase 4 study to evaluate the long-term effects of the Aduhelm (aducanumab-avwa) 100 mg/mL solution for injection this time, with a focus on recruiting more patients from minority groups. The...

Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have announced topline data from a Phase 1b study of BIIB080/IONIS-MAPTRx in mild Alzheimer's disease. The trial met its primary objective of safety and tolerability. It demonstrated dose-dependent...

An analysis of Phase 3 data presented by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) of its Alzheimer's therapy Aduhelm (aducanumab) showed the treatment slowed cognitive, functional, and behavioral decline in the early stages of the disease. Treatment...

A pair of large hospitals have declined to administer Biogen Inc’s (NASDAQ: BIIB) Alzheimer’s treatment Aduhelm, Wall Street Journal reported. The Cleveland Clinic and Mount Sinai Health System in New York said they wouldn’t administer the drug to patients amid a...

Biogen Inc. (NASDAQ: BIIB) shares came under pressure Friday after the Food and Drug Administration called for an investigation into the approval of the company's Alzheimer's treatment Aduhelm. What Happened: In a letter disclosed publicly, FDA Acting Commissioner Janet Woodcock...

Biogen Inc. (NASDAQ: BIIB) shares are lower after the company announced an updated label for its recently-approved Alzheimer's treatment Aduhelm. What Happened: Biogen, which is partnering with Japan's Eisai Co., Ltd. (OTC: ESALY) for Aduhelm, said the Food and Drug Administration updated...

Biogen Inc. (NASDAQ: BIIB) stock is seeing muted sentiment Tuesday as it emerges from the euphoria over Aduhelm approval, with the most recent trigger being lukewarm data for a partnered program. The Biogen Analyst: Geoff Meacham reiterated a Buy rating on Biogen shares and raised the price...

Biogen Inc. (NASDAQ: BIIB) made history of sorts with the FDA approval for its Alzheimer's treatment Aduhelm. Notwithstanding the still-raging debate over the decision, an analyst at Morgan Stanley is looking past the decision and into key upcoming catalysts that could provide significant...